Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Zealand Pharma A/S ADR (ZEAL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 377,918
  • Shares Outstanding, K 30,750
  • Annual Sales, $ 21,230 K
  • Annual Income, $ -41,360 K
  • 36-Month Beta 2.28
  • Price/Sales 17.81
  • Price/Cash Flow N/A
  • Price/Book 7.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.62
  • Number of Estimates 1
  • High Estimate -0.62
  • Low Estimate -0.62
  • Prior Year -0.58
  • Growth Rate Est. (year over year) -6.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.51 +6.26%
on 11/14/18
14.40 -15.07%
on 10/17/18
-1.83 (-13.02%)
since 10/16/18
3-Month
11.51 +6.26%
on 11/14/18
18.91 -35.33%
on 09/18/18
-1.42 (-10.40%)
since 08/16/18
52-Week
11.51 +6.26%
on 11/14/18
18.91 -35.33%
on 09/18/18
-2.50 (-16.97%)
since 11/16/17

Most Recent Stories

More News
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants

Company announcement - No. 22 / 2018

ZEAL : 12.23 (-0.49%)
Blog Exposure - Zealand's End-of-Phase-2 Meeting with FDA Confirmed the Path Forward for Phase-3 Program of Glepaglutide for Short Bowel Syndrome

Stock Monitor: Cytokinetics Post Earnings Reporting

ZEAL : 12.23 (-0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

See More Share

Trade ZEAL with:

Business Summary

Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark.

See More

Key Turning Points

2nd Resistance Point 12.52
1st Resistance Point 12.37
Last Price 12.23
1st Support Level 12.07
2nd Support Level 11.92

See More

52-Week High 18.91
Fibonacci 61.8% 16.08
Fibonacci 50% 15.21
Fibonacci 38.2% 14.34
Last Price 12.23
52-Week Low 11.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar